Medical Equipment & Devices
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Following FY22 results, brokers set higher price targets for ResMed on average and expect market share gains
Aug 15 2022
Dedicated lung imaging pioneer 4D medical sees itself as a software company, with lots of future potential, including from the US military
Aug 08 2022
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| CBL | CONTROL BIONICS LIMITED | $0.18 | $0.66 | $0.12 |
$0.85 |
|
| COH | COCHLEAR LIMITED | $208.36 | $236.43 | $178.55 | 44.1 |
$217.783 |
| EBR | EBR SYSTEMS INC | $0.52 | $1.10 | $0.33 |
$1.38 |
|
| FPH | FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED | $16.83 | $33.01 | $16.18 | 51.9 |
$19.50 |
| IDX | INTEGRAL DIAGNOSTICS LIMITED | $2.80 | $5.13 | $2.38 | 20.6 |
$3.086 |
| IME | IMEXHS LIMITED | $0.47 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IPD | IMPEDIMED LIMITED | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MX1 | MICRO-X LIMITED | $0.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NAN | NANOSONICS LIMITED | $3.50 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PME | PRO MEDICUS LIMITED | $53.16 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RMD | RESMED INC | $33.81 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SOM | SOMNOMED LIMITED | $1.40 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TRJ | SOMNOMED LIMITED | $2.04 | $xx.xx | $xx.xx | xx.x | xx.xx |
| VHT | VOLPARA HEALTH TECHNOLOGIES LIMITED | $0.55 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Treasure Chest: The Outlook For Cochlear
Jul 27 2022
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea regards Cochlear
Nanosonics’ Q4 Surprises, But Brokers See Risk
Jul 27 2022
Nanosonics’ June quarter update proved a positive surprise but most brokers cannot get past the many risks, also finding the shares look expensive
Benefits In View For Radiology AI Adopters
Jul 11 2022
After a huge step up in funding over the last three years, artificial intelligence in radiology may be approaching wider adoption across the sector
Brokers Divided Over ResMed’s SaaS Acquisition
Jun 16 2022
Following ResMed’s purchase of Medifox Dan, brokers remain upbeat though some question the benefits of SaaS acquisitions to date
Shortages Chip Away At ResMed’s Big Break
Mar 30 2022
ResMed has struggled to realise the benefit promised by a major competitor recall and heightened demand amid a global shortage of semiconductor chips necessary for device production
Opportunity for Fisher & Paykel Healthcare
Mar 25 2022
With a potential end in sight for Fisher & Paykel Healthcare’s covid benefits the company looks to prove its ventilation devices have a place outside of intensive care units and rebuild utilisation rates for a sustainable outlook
Distribution Anxiety For Nanosonics
Feb 10 2022
Disappointment over first half sales and an abrupt change to a US distribution agreement sent shares of Nanosonics lower, though some brokers see value emerging
Brokers Awake To ResMed’s Potential
Jan 31 2022
Brokers remain positive on the outlook for ResMed due to a new product launch and the potential for both increased market share and the easing of supply chain pressures
Covid Benefits F&P Healthcare, For Now
Dec 06 2021
Normalisation appears to be on the horizon for Fisher & Paykel Healthcare, after hardware sales have continued to benefit from covid hospitalisations longer than anticipated
Will Shortages Limit Upside For ResMed?
Nov 01 2021
Some market share is likely to stick with ResMed as Philips struggles to replace its recalled device. Yet will supply chain constraints limit the benefit?
Latest News
| 1 |
ASX Winners And Losers Of Today – 30-09-22Sep 30 2022 - Daily Market Reports |
| 2 |
Weekly Top Ten News Stories – 30 September 2022Sep 30 2022 - Weekly Reports |
| 3 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
| 4 |
Next Week At A Glance – 3-7 Oct 2022Sep 30 2022 - Weekly Reports |
| 5 |
ESG Focus: Biodiversity Ready To RollSep 30 2022 - ESG Focus |